In a move poised to reshape the maternal health technology landscape, Laborie Medical Technologies announced plans to acquire the JADA System, a postpartum uterine bleeding device developed by Organon, for up to $465 million.
The acquisition, unveiled Friday and guided by Simpson Thacher & Bartlett LLP and Cooley LLP, includes an upfront payment of $440 million and an additional $25 million contingent on 2026 revenue milestones.
A Lifesaving Device Goes Global
The JADA System, cleared by the U.S. Food and Drug Administration (FDA), is designed to control and treat abnormal postpartum uterine bleeding or hemorrhage — one of the leading causes of maternal mortality. The device is already available in over 2,000 U.S. hospitals and has reached more than 20 countries.
Headquartered in Portsmouth, New Hampshire, Laborie specializes in medical technology across urology, gastroenterology, and obstetrics, supported by capital markets powerhouse Patricia Industries.
“Childbirth is one of the most personal and profound moments in a woman’s life, and every mother deserves to feel supported throughout it,” said Chris Smith, Laborie’s President and CEO. “The JADA System helps care teams provide treatment when it matters most. We are proud to carry this mission forward and excited to welcome the talented JADA team to accelerate our growth in the obstetrics market.”
We are The People's Media. USA Herald covers everything from breaking news to investigative journalism. We also report on politics on the State and National levels.
